Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

747509

registered interest
date	03/07/2017
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Universal Credit
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, what progress has been made on the trial of in-work progression for universal credit claimants; and if he will make a statement.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	2379
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>National roll-out of the in-work progression randomised control trial is now complete. Recruitment onto the trial ceased on 31 March 2017, and the trial will continue to run until 31 March 2018. We expect to publish the full evaluation report in summer 2018.</p> answering member constituency East Hampshire answering member printed Damian Hinds question first answered 06/07/2017 09:17:44 answering member 3969 label Biography information for Damian Hinds
tabling member	478 label Biography information for Lord Field of Birkenhead

381165

registered interest
date	15/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what information he has on whether his Department had knowledge prior to 2000 of the fact that the anti-convulsant drug Epilim, Sanofi Aventis, known previously as Sanofi Pharma, was potentially teratogenic to foetuses.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	2379
answer	answer is ministerial correction date of answer 22/06/2015 answer text <p>The information available for Epilim in 1974 contained a warning that the compound was known to be teratogenic in animals and that any known hazards should be balanced against benefit when used in human pregnancy.</p><p> </p><p> </p><p> </p><p>In January 1983 the Committee on Safety of Medicines published warnings about reported increase of incidence of congenital malformations in association with sodium valproate; this was based mainly on various epidemiological studies. Further advice was published in June 1993 in relation to an increased risk of neural tube defects associated with sodium valproate, the need to inform women of the potential consequences and for healthcare professionals to refer the patient to an appropriate specialist, in addition to ensuring that appropriate screening is in place.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/06/2015 13:41:17 answering member 4020 label Biography information for George Freeman
tabling member	3958 label Biography information for Fiona Bruce